scispace - formally typeset
Open AccessJournal Article

Gender difference in patients with hepatocellular carcinoma.

Reads0
Chats0
TLDR
Hepatocellular carcinoma was more aggressive in male but median survival time was not significant between groups, and the viral C etiology was statistically more frequent in women than in men.
Abstract
Background Hepatocellular carcinoma represents the fifth most common cancer worldwide and account for approximately 90% of primary liver cancer. Men have a higher prevalence than women; the sex ratio varies between 2:1 and 4:1, depending on the geographic region. Aim To determine the influence of gender on the clinicopathologic characteristics and survival of patients with hepatocellular carcinoma. Methods A retrospective analysis of medical records was performed in 63 patients with hepatocellular carcinoma and their clinicopathologic features and survival were compared in relation to gender. The data was summarized by descriptive statistics and analysed with SPSS version 11.5. Results Among these patients, 36 were men (57.1%) with male-to female ratio of 2:1.5, the mean female age was 59.8 years (p=0.054). Serum albumin level was significantly lower in women (p=0.0061).The average size of the tumor was 45.8mm and the difference was not significant (p=0.638). Hepatocellular carcinoma was significantly more prevalent among 16 men with post viral B cirrhosis (p=0.04). The main reason for therapeutic abstention was multifocal character of the hepatocellular carcinoma. The median survival time (6.52 months) was not different between the 2 groups. Conclusion At diagnosis, men were younger than women. The viral C etiology was statistically more frequent in women than in men. Hepatocellular carcinoma was more aggressive in male but median survival time was not significant between groups. Screening and early treatment can limit this problem.

read more

Citations
More filters
Journal ArticleDOI

Microwave ablation compared with radiofrequency ablation for treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis.

TL;DR: MWA is at least as safe and effective as RFA for treating liver cancer and demonstrated significantly reduced LTP rates, according to systematic review and meta-analysis.
Journal ArticleDOI

Gender differences in liver disease and the drug-dose gender gap.

TL;DR: This review reports the data found in the literature concerning the gender‐related differences for the most representative hepatic diseases.
Journal ArticleDOI

Marital status and survival in patients with primary liver cancer.

TL;DR: In primary liver cancer patients, married patients enjoyed survival benefits while widowed persons suffered survival disadvantages in both overall survival and cancer-specific survival.
Journal ArticleDOI

Trends in hepatocellular carcinoma research from 2008 to 2017: a bibliometric analysis

TL;DR: The amount of papers published in HCC research has kept increasing since 2008, but the United States was still the dominant country and the keyword “transarterial chemoembolization” ranked first in the research front-line.
Journal ArticleDOI

Serotonin Activated Hepatic Stellate Cells Contribute to Sex Disparity in Hepatocellular Carcinoma.

TL;DR: Investigating the role of serotonin on its contribution of sex discrepancy during HCC found a predominant serotonin synthesis and accumulation in males resulted in higher HSC density and activation as well as Tgfb1 expression, thus accelerating HCC carcinogenesis in males.
Related Papers (5)